|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hepatocellular carcino- ma arising in a pigmented telangiectatic adenoma with nuclear beta- catenin and glutamine synthetase positivity: case report and review of the literature显示文摘 | Hechtman J F Raoufi M Fiel M I | 2012 | Am J Surg Pathol2012，35，6： | 1 |
| 2 | Aggressive surgical resec-tion for hilar cholangiocarcinoma:is it justified? Auditof a single center's experience显示文摘 | Konstadoulakis M M Roayaie S? Gomatos I P LabowD Fiel M I Miller C M | 2008 | Am J Surg2008，196，： | 1 |
| 3 | Dendritic cell regulation of carbon tetrachloride- induced murine liver fibrosis regression显示文摘 | JIAO J SASTRE D FIEL M I | 2012 | Hepatology2012，55，1： | 1 |
| 4 | Intercalative and nonintercalative binding of large cationic porphyrin ligands to calf thymus DNA 显示文摘 | Carvlin M J Fiel R J | 1983 | Nucleic Acids Research1983，11，： | 1 |
| 5 | Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression显示文摘 | Jiao J Sastre D Isabel Fiel M | | 0，，01： | 1 |
| 6 | Intercalative and noninterca1ative binding of large cationic porphyrin ligands to calf thymus显示文摘 | Carvlin M J Fiel R J | 1983 | Nucl Acid Res1983，，： | 1 |
| 7 | The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan 显示文摘 | Alonen A Fiel M Kostianinen R | 2008 | Biochem Pharmacol2008，76，6： | 1 |
| 8 | Intercalative and nonintercalative binding of large cationic porphyrin ligands to calf thymus DNA显示文摘 | Carvlin M J Fiel R J | 1983 | Nucleic Acids Research1983，11，： | 1 |
| 9 | Intercalative and noninterca1ative binding of large cationic porphyrin ligands to calf thymus显示文摘 | Carvlin M J Fiel R J | 1983 | Nucl Acid Res1983，，： | 1 |
| 10 | Asbestos-related pleural disease and asbestosis: acomparison of CT and chest radiography 显示文摘 | Friedman A C Fiel S B Fisher M S | 1988 | AJR1988，150，2： | 1 |
| 11 | Increased hepatic iron deposition resulting from treatment of chronic hepatitis C with ribavirin显示文摘 | FIEL MI SCHIANO TD GUIDO M etal | 2000 | Am J Clin Pathol2000，113，1： | 1 |
| 12 | Recurrent hepatitis C after retransplantation : factors affecting graft and patient outcome 显示文摘 | Carmiel-Haggai M Fiel M I Gaddipati H C | 2005 | Liver Transpl2005，11，12： | 1 |
| 13 | Intercalative and nonintercalative binding of large cationic porphyrin ligands to calf thymus DNA显示文摘 | FIEL R J | 1983 | Nucleic Acids Res1983，11，： | 1 |
| 14 | Use of livers with microvesicular fat safely expands the donor pool显示文摘 | Fishbein T M Fiel M I Emre S | 1997 | Transplantat ion1997，64，2： | 1 |
| 15 | Use of livers with microvascular fat safely expands the donor pool显示文摘 | Fiel I M Emre S | 1997 | Transplantation1997，64，2： | 1 |
| 16 | Exercise in creases muscle GLUT4 levels and insulin action insubject swith impaired glueose tolerance 显示文摘 | HUGHES V A FIATARONE M A FIELEING R A | 1993 | Am J Physiol1993，264，61： | 1 |
| 17 | Intercalative and nonintercalative binding of large cationic porphyrin ligands to calf thymus DNA显示文摘 | CARVLIN M J FIEL R J | 1983 | Nucleic Acids Res1983，11，15： | 1 |
| 18 | Intercalative and nonintercalative binding of large cationic porphyrin ligands to calf thymus DNA显示文摘 | Carvlin M J Fiel R J | 1983 | Nucl Acid Res1983，11，： | 1 |
| 19 | Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration显示文摘 | Bhat R V Shanley J Correll M P Fieles W E Keith R A Scott C W Lee C M | | 0，，： | 1 |
| 20 | Utility of the low-accelerating-dose regimen in 182 liver recipients with recurrent hepatitis C virus显示文摘AIM: To describe our experience using a low-acceleratingdose regimen(LADR) with pegylated interferon alpha-2a and ribavirin in treatment of hepatitis C virus(HCV) recurrence. METHODS: From 2003, a protocolized LADR strategy was employed to treat liver transplant(LT) recipients with recurrent HCV at our institution. Medical records of 182 adult patients with recurrent HCV treated with LADR between 1/2003 and 1/2011 were reviewed. Histopathology from all post-LT liver biopsies were reviewed in a blinded fashion. Paired recipient and donor IL28 B status were assessed. A novel technique was employed to ascertain recipient and donor IL28B(rs12979860) Gt data using DNA extracted from archival FFPE tissue from explanted native livers and donor gallbladders respectively. The primary endpoint was SVR; secondary endpoints examined include(1) patient and graft survival;(2) effect of anti-viral therapy on liver histology(fibrosis and inflammation);(3) incidence of on-treatment development of ACR, CDR, or PCH;(4) association of recipient and donor IL28 B genotype with SVR; and(5) incidence of antiviral therapy-associated adverse events(anemia, leukopenia, thrombocytopenia, depression) and hepatic decompensation.RESULTS: The overall SVR rate was 38%(29% Gt1, 67% Gt2, 86% Gt3 and 58% Gt4). HCV Gt(P < 0.0001), donor age(P = 0.003), cytomegalovirus mismatch(P = 0.001), baseline serum bilirubin(P = 0.002), and baseline viral load(P = 0.04) were independent predictors for SVR. SVR rates were significantly higher in the recipient-CC/donor-non CC pairs(P = 0.007). Neither baseline fibrosis nor change in fibrosis stage after anti-viral therapy were associated with SVR. Fibrosis progressed in 72% of patients despite SVR. Median graft survival was 91 mo. Five-year patient survival was superior in patients who achieved SVR(97% vs 82%, P = 0.001). Pre-treatment ALP ≥ 150 U/L(P = 0.01), total bilirubin ≥ 1.5 mg/d L(P = 0.001) and creatinine ≥ 2 mg/d L(P = 0.001) were independently associated with patient survival. Only 13% of patients achieving SVR died during the followup period. Treatment discontinuation and treatmentrelated mortality occurred in 35% and 2.2% of patients, respectively. EPO, G-CSF and blood transfusion were needed in 89%, 40% and 23% of patients, respectively. Overall hospitalization rate for treatment-related serious adverse events was 21%. Forty-six(25%) of the patients were deceased; among those who died, 25(54%) were due to liver-related complications, and 4 deaths(9%) occurred while receiving therapy(2 patients experienced hepatic decompensation and 2 sepsis). CONCLUSION: LADR strategy remains relevant in managing post-LT recurrent HCV where access to DAAs is limited. SVR is associated with improved survival, but fibrosis progression still occurs. | Kieron BL Lim Hamid R Sima M Isabel Fiel Viktoriya Khaitova John T Doucette Maria Chernyiak Jawad Ahmad Nancy Bach Charissa Chang Priya Grewal Leona Kim-Schluger Lawrence Liu Joseph Odin Ponni Perumalswami Sander S Florman Thomas D Schiano | 2015 | World Journal of Gastroenterology2015，21，20： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员